Abstract 1673P
Background
Imposter Syndrome (IS) is defined as “the inability to internalize achievement and a tendency to attribute success to external factors such as luck, error, or personal connections. It has been associated with psychological distress, emotional suffering, and significant mental health issues. It has also been associated with Burnout (BO), characterized by the emotional exhaustion of individuals in their careers, depersonalization toward other individuals, and a decrease in the sense of personal accomplishments. The study aimed to evaluate the factors associated with IS and its association with BO in medical oncologists (MOs).
Methods
A cross-sectional study was conducted focusing on the MOs actively working in the field. They were invited to the study via mailing list. The sociodemographic and academic data were collected. The IS scores (ISS) was tested using the Clance imposter phenomenon Scale and BO was tested by using the Maslach burnout inventory. The subscales of BO; emotional exhaustion (EE), depersonalization (DP), and personal accomplishment (PA) were analyzed. The characteristics associated with IS and BO were tested by univariate and multivariate analysis.
Results
In the study, 417 MOs with a median age of 40(29-68) were evaluated. The mean of ISS was 50.8+/-15.3, and 122(29.3%) participants had high ISS. The multivariate analysis revealed that female gender was the only factor associated with high ISS (OR: 1.85, CI95%, 1.1- 2.9, p=0.009). While there was a strong positive correlation between ISS and EE (r=0.54, p<0.001) and DP (r=0.48, p<0.001), a strong and negative correlation was found between ISS and PA score (r= -0.41, p<0.001). In the multivariate analysis; high ISS score was the only statistically significant parameter associated with a high EE score (OR:5.03, CI 95% 3.1-8.0, p<0.001), high DP scores (OR=3.4, CI 95% 1.8- 6.5, p<0.001) and low PA scores. (OR=3.73, CI 95% 1.9- 7.1, p<0.001).
Conclusions
The results of the study indicated that IS is prevalent in MOs. The MOs with IS were more emotionally exhausted and more depersonalized. In addition, they had less feeling of personal accomplishment. The IS and its consequences on MOs should be further studied and the strategies to cope with IS should be developed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1636P - Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Presenter: Renée Bultijnck
Session: Poster session 11
1637P - Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
Presenter: Neeraj Agarwal
Session: Poster session 11
1638P - Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
Presenter: Neal Shore
Session: Poster session 11
1639P - Self efficacy in people with prostate cancer in the UK: A large, digital survey
Presenter: Joe O'Sullivan
Session: Poster session 11
1640P - Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients
Presenter: Ziyun Wang
Session: Poster session 11
1641P - Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Presenter: Christos Kyriakopoulos
Session: Poster session 11
1642P - Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
Presenter: Charles Vauchier
Session: Poster session 11
1643P - Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Presenter: Bicky Thapa
Session: Poster session 11
1644P - PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Lana Broer
Session: Poster session 11
1645P - Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
Presenter: Marta Garcia De Herreros
Session: Poster session 11